Chieko Ishiguro

698 total citations
48 papers, 408 citations indexed

About

Chieko Ishiguro is a scholar working on Toxicology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Chieko Ishiguro has authored 48 papers receiving a total of 408 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Toxicology, 13 papers in Epidemiology and 10 papers in Infectious Diseases. Recurrent topics in Chieko Ishiguro's work include Pharmacovigilance and Adverse Drug Reactions (14 papers), SARS-CoV-2 and COVID-19 Research (8 papers) and Vaccine Coverage and Hesitancy (8 papers). Chieko Ishiguro is often cited by papers focused on Pharmacovigilance and Adverse Drug Reactions (14 papers), SARS-CoV-2 and COVID-19 Research (8 papers) and Vaccine Coverage and Hesitancy (8 papers). Chieko Ishiguro collaborates with scholars based in Japan, United States and United Kingdom. Chieko Ishiguro's co-authors include Yoshiaki Uyama, Haruhisa Fukuda, Yoshinori Takeuchi, Rei Ono, Kosuke Kiyohara, Takashi Omori, Tosiya Sato, Toshiharu Fujita, Yosuke Fujii and Tatsuo Akechi and has published in prestigious journals such as PLoS ONE, European Heart Journal and Clinical Pharmacology & Therapeutics.

In The Last Decade

Chieko Ishiguro

42 papers receiving 399 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chieko Ishiguro Japan 13 72 67 66 62 61 48 408
Andreas D. Meid Germany 17 48 0.7× 45 0.7× 196 3.0× 88 1.4× 240 3.9× 59 830
Cynthia Kornegay United States 11 41 0.6× 105 1.6× 81 1.2× 119 1.9× 72 1.2× 16 753
Stéphanie Tcherny‐Lessenot France 13 84 1.2× 19 0.3× 28 0.4× 58 0.9× 58 1.0× 29 510
Sonja Gandhi Canada 14 43 0.6× 28 0.4× 112 1.7× 123 2.0× 74 1.2× 21 845
Carlos A. Álvarez United States 15 25 0.3× 111 1.7× 86 1.3× 104 1.7× 80 1.3× 64 747
Yvon Merlière France 10 36 0.5× 27 0.4× 94 1.4× 142 2.3× 107 1.8× 13 714
Esther H. Zhou United States 16 98 1.4× 24 0.4× 37 0.6× 63 1.0× 78 1.3× 47 582
Sandra Vezmar Kovačević Serbia 15 22 0.3× 33 0.5× 39 0.6× 52 0.8× 63 1.0× 56 576
Craig Heise United States 10 26 0.4× 71 1.1× 111 1.7× 47 0.8× 16 0.3× 29 385
Olga Laosa Spain 12 16 0.2× 29 0.4× 47 0.7× 72 1.2× 116 1.9× 21 675

Countries citing papers authored by Chieko Ishiguro

Since Specialization
Citations

This map shows the geographic impact of Chieko Ishiguro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chieko Ishiguro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chieko Ishiguro more than expected).

Fields of papers citing papers by Chieko Ishiguro

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chieko Ishiguro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chieko Ishiguro. The network helps show where Chieko Ishiguro may publish in the future.

Co-authorship network of co-authors of Chieko Ishiguro

This figure shows the co-authorship network connecting the top 25 collaborators of Chieko Ishiguro. A scholar is included among the top collaborators of Chieko Ishiguro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chieko Ishiguro. Chieko Ishiguro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yamazaki, Hiroshi, Ko Nakajo, Naoki Hirose, et al.. (2025). Regulatory-required post-marketing database studies in Japan could be leveraged to assess important potential risks as well as identified risks. Frontiers in Pharmacology. 16. 1565314–1565314.
2.
Ishiguro, Chieko, et al.. (2024). Development and Validation of Claims-based Algorithms for Identifying Hospitalized Patients With COVID-19 and Their Severity in 2020 and 2021. Journal of Epidemiology. 34(10). 485–492. 2 indexed citations
3.
Ishiguro, Chieko, et al.. (2024). Association between mRNA COVID-19 vaccine boosters and mortality in Japan: The VENUS study. Human Vaccines & Immunotherapeutics. 20(1). 2350091–2350091. 1 indexed citations
4.
5.
6.
7.
Ishiguro, Chieko, et al.. (2023). Bivalent Vaccine Effectiveness Among Adults Aged ≥65 Years During the BA.5-Predominant Period in Japan: The VENUS Study. Open Forum Infectious Diseases. 10(10). ofad475–ofad475. 3 indexed citations
8.
9.
10.
Kinoshita, Yuki, et al.. (2023). Characterizing Granulocytopenia Associated with Thiamazole in Patients with Hyperthyroidism Based on Real‐World Data from the MID‐NET in Japan. Clinical Pharmacology & Therapeutics. 113(4). 924–931. 2 indexed citations
11.
12.
Ishiguro, Chieko, et al.. (2022). Effectiveness of a Third Dose of COVID-19 mRNA Vaccine During the Omicron BA.1- and BA.2-Predominant Periods in Japan: The VENUS Study. Open Forum Infectious Diseases. 9(12). ofac636–ofac636. 4 indexed citations
13.
14.
Iwagami, Masao, Chieko Ishiguro, Norihisa Yamamoto, et al.. (2022). Updated report of COVID-19 vaccine safety monitoring in Japan: Booster shots and paediatric vaccinations. The Lancet Regional Health - Western Pacific. 27. 100600–100600. 1 indexed citations
15.
16.
Iwagami, Masao, Chieko Ishiguro, Norihisa Yamamoto, et al.. (2022). Safety monitoring of COVID-19 vaccines in Japan. The Lancet Regional Health - Western Pacific. 23. 100442–100442. 20 indexed citations
17.
Ando, Takashi, et al.. (2021). Effect of Hepatitis C Drugs on Blood Coagulability in Patients on Warfarin Using the Medical Information Database Network (MID-NET®) in Japan. Therapeutic Innovation & Regulatory Science. 55(3). 539–544. 3 indexed citations
18.
Takeuchi, Yoshinori, Takashi Ando, Chieko Ishiguro, & Yoshiaki Uyama. (2016). Risk of Acute Asthma Attacks Associated With Nonsteroidal Anti-inflammatory Drugs: A Self-Controlled Case Series. Therapeutic Innovation & Regulatory Science. 51(3). 332–341. 5 indexed citations
19.
Takeuchi, Yoshinori, et al.. (2015). Atypical Antipsychotics and the Risk of Hyperlipidemia: A Sequence Symmetry Analysis. Drug Safety. 38(7). 641–650. 26 indexed citations
20.
Ishiguro, Chieko, et al.. (2008). Assessing the Effects of Non-steroidal Anti-inflammatory Drugs on Antihypertensive Drug Therapy Using Post-Marketing Surveillance Database. Journal of Epidemiology. 18(3). 119–124. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andreas D. Meid Breakdown of academic impact, for papers by Cynthia Kornegay Breakdown of academic impact, for papers by Stéphanie Tcherny‐Lessenot Breakdown of academic impact, for papers by Sonja Gandhi Breakdown of academic impact, for papers by Carlos A. Álvarez Breakdown of academic impact, for papers by Yvon Merlière Breakdown of academic impact, for papers by Esther H. Zhou Breakdown of academic impact, for papers by Sandra Vezmar Kovačević Breakdown of academic impact, for papers by Craig Heise Breakdown of academic impact, for papers by Olga Laosa
Rankless by CCL
2026